Current Report Filing (8-k)
December 21 2016 - 6:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 19, 2016
|
|
|
TRACON Pharmaceuticals, Inc.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
001-36818
|
34-2037594
|
(State or other jurisdiction
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
of incorporation)
|
|
|
|
|
|
|
8910 University Center Lane, Suite 700
San Diego, California
|
92122
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Registrant’s telephone number, including area code:
(858) 550-0780
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
5.02
.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
|
On December 19, 2016, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of
TRACON Pharmaceuticals, Inc.
(the “Company” or “TRACON”) approved a bonus plan (the “Bonus Plan”), which sets forth the terms of the annual incentive bonus opportunity for eligible employees of the Company. Under the Bonus Plan, the Company’s executive officers are eligible to receive bonus awards that are determined based on the achievement of the Company’s corporate goals for the applicable plan year and an evaluation of individual performance measured against pre-established individual performance goals for the applicable plan year. Corporate goals for the 2016 plan year were previously established on January 21, 2016. Bonuses, if any, under the Bonus Plan will be payable in cash or equity, or a combination of both, after the end of the applicable plan year and no later than December 31 of the following year.
Item 9.01.
|
Financial Statements and Exhibits.
|
|
|
|
10.1
|
|
TRACON Pharmaceuticals, Inc. Bonus Plan.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
TRACON Pharmaceuticals, Inc.
|
Dated: December 20, 2016
|
By:
|
/s/ Charles P. Theuer, M.D., Ph.D.
|
|
|
|
Charles P. Theuer, M.D., Ph.D.
President and Chief Executive Officer
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
10.1
|
|
TRACON Pharmaceuticals, Inc. Bonus Plan.
|
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From Jul 2024 to Aug 2024
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From Aug 2023 to Aug 2024